[{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"FGFR3 gene","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"FGFR3 gene","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"FGFR3 gene","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"FGFR3 gene","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"FGFR3 gene","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Masitinib Mesylate","moa":"FGFR3 gene","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ European Investment Bank","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ European Investment Bank"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"PDGFRA","graph1":"Oncology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"University of Chicago","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ University of Chicago","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ University of Chicago"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"PDGFRA","graph1":"Oncology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"PDGFRA","graph1":"Immunology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"PDGFRA","graph1":"Immunology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"TYK","graph1":"Oncology","graph2":"IND Enabling","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"TYK","graph1":"Oncology","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"TYK","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"Stem Cell growth factor receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"FGFR3 gene","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"CSF1R","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"Sodium channel alpha subunits","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Masitinib Mesylate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AB Science \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Masitinib Mesylate

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : AB1010 (masitinib) is a tyrosine kinase inhibitor, small molecule drug, being evaluated in phase 3 in combination with Rilutek (riluzole) for the treatment of amyotrophic lateral sclerosis.

                          Brand Name : AB1010

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 17, 2024

                          Lead Product(s) : Masitinib Mesylate,Riluzole

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : AB1010 (masitinib) is a small molecule drug that selectively inhibits specific tyrosine kinases such as colony-stimulating factor 1 receptor, being evaluated with Isoquercetin for COVID-19.

                          Brand Name : AB1010

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 08, 2024

                          Lead Product(s) : Masitinib Mesylate,Isoquercitrin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : AB1010 (masitinib) is a tyrosine kinase inhibitor, small molecule drug, being evaluated in phase 3 in combination with Rilutek (riluzole) for the treatment of amyotrophic lateral sclerosis.

                          Brand Name : AB1010

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 29, 2024

                          Lead Product(s) : Masitinib Mesylate,Riluzole

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : AB1010 (masitinib) is a tyrosine kinase inhibitor, small molecule drug. It is being evaluated in phase 3 clinical studies in combination with Rilutek (riluzole) for amyotrophic lateral sclerosis.

                          Brand Name : AB1010

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 26, 2024

                          Lead Product(s) : Masitinib Mesylate,Riluzole

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : AB1010 (masitinib), is one of the most promising drugs in ALS that has just been submitted to the EMA conditional approval process. Masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurologica...

                          Brand Name : AB1010

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 18, 2023

                          Lead Product(s) : Masitinib Mesylate

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : AB1010 (masitinib), is one of the most promising drugs in ALS that has just been submitted to the EMA conditional approval process. Masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurologica...

                          Brand Name : AB1010

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 01, 2023

                          Lead Product(s) : Masitinib Mesylate

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : AB1010 (masitinib) is a tyrosine kinase inhibitor, emphasizes the neuro-inflammatory activity of ALS by targeting macrophages, mast cells, and microglia cells. It downregulates the proinflammatory cytokines, indirectly reduces inflammation, and induces n...

                          Brand Name : AB1010

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 09, 2023

                          Lead Product(s) : Masitinib Mesylate,Riluzole

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The proceeds will be used to fund the development of AB1010 (masitinib) for the treatment of amyotrophic lateral sclerosis and the development of the microtubule destabilizer agents (MDA) platform, with the clinical development of AB8939 in refractory ac...

                          Brand Name : AB1010

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 24, 2023

                          Lead Product(s) : Masitinib Mesylate,Riluzole

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : $16.4 million

                          Deal Type : Private Placement

                          blank

                          09

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : AB1010 (masitinib), a tyrosine kinase inhibitor, emphasizes the neuro-inflammatory activity of ALS by targeting macrophages, mast cells, and microglia cells. It downregulates the proinflammatory cytokines, indirectly reduces inflammation, and induces neu...

                          Brand Name : AB1010

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 18, 2023

                          Lead Product(s) : Masitinib Mesylate,Riluzole

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : AB1010 (masitinib), is one of the most promising drugs in ALS that has just been submitted to the EMA conditional approval process. Masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurologica...

                          Brand Name : AB1010

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 04, 2023

                          Lead Product(s) : Masitinib Mesylate

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank